Capturing Circulating Prostate Cancer Cells in a Microfluidics Chip
October 2, 2012 | Terry Sharrer
Researchers at Cornell have reported designing a microfluidics chip (using anti-prostate specific membrane antigens as the capture molecule) that has far greater specificity and sensitivity than any existing commercial assay (i.e. up to 400 fold greater sensitivity). They also assert: “These measurements constitute the first functional assays of drug-target engagement in living circulating tumor cells and therefore have the potential to enable longitudinal monitoring of target response and inform the development of new anticancer agents.” MORE